FDA deems Sanofi/Genzyme drug olipudase alfa 'breakthrough'

The FDA has granted breakthrough therapy designation (BTD) to an experimental medicine from Sanofi and its US Genzyme unit for olipudase alfa, an experimental enzyme replacement therapy being investigated to treat Niemann-Pick disease type B (NPB).